Capricor Therapeutics (CAPR) Net Cash Flow (2010 - 2026)

Capricor Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$182.4 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 1141.99% year-over-year to -$182.4 million in Q1 2026; TTM through Mar 2026 was $76.6 million, a 239.36% increase from a year earlier, with the FY2025 full-year figure at $276.6 million, up 8215.36% from the prior year.
• Net Cash Flow slipped to -$182.4 million in Q1 2026 per CAPR's latest filing, from $268.3 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $268.3 million in Q4 2025 and bottomed at -$182.4 million in Q1 2026.
• The 5-year median for Net Cash Flow is -$768395.0 (2023), against an average of $4.1 million.
• Across the five-year window, Net Cash Flow surged 6867.31% in 2024 and tumbled 1141.99% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at $1.2 million in 2022, then jumped by 380.01% to $5.7 million in 2023, then tumbled by 1099.8% to -$57.1 million in 2024, then surged by 570.02% to $268.3 million in 2025, then plunged by 167.98% to -$182.4 million in 2026.
• Per Business Quant, the three latest CAPR Net Cash Flow figures stand at -$182.4 million (Q1 2026), $268.3 million (Q4 2025), and -$3.7 million (Q3 2025).